Equitec Specialists’s Inovio Pharmaceuticals INO Stock Holding History

Equitec Specialists’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,940	Closed	-$327K	–	43
2021 Q1	$327K	Buy	+2,940	New	+$387K	0.06%	101

Other funds holding INO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Equitec Specialists's INO Position: Q2 2021 in Review

Equitec Specialists sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 2,940 shares — an estimated $327K sold.

Equitec Specialists first reported a position in INO in Q1 2021 and held it in 1 quarter. The position peaked at $327K in Q1 2021. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

Equitec Specialists reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Equitec Specialists sold 2,940 Inovio Pharmaceuticals shares in Q2 2021, an estimated $327K.
Equitec Specialists first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Equitec Specialists's Inovio Pharmaceuticals position peaked at $327K in Q1 2021.
211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Equitec Specialists's 13F filing for Q2 2021, filed 20 Jul 2021.